Erenumab is a anti-CGRP monoclonal antibody that blocks the calcitonin gene-related peptide (CGRP) receptor which is a heterodimer of calcitonin gene-related peptide type 1 receptor and its transport protein receptor activity-modifying protein 1. It is in advanced development for the treatment of migraine with phase 3 trials complete. It is likely the dose will be 70mg monthly subcutaneously with the expectation that 50% of sufferers will achieve a 50% reduction in headache frequency.
- ↑ Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet. Neurology. 2017 Jun; 16(6):425-434.(Print-Electronic) (Link to article – subscription may be required.)
- ↑ Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA. A Controlled Trial of Erenumab for Episodic Migraine. The New England journal of medicine. 2017 Nov; 377(22):2123-2132.(Print) (Link to article – subscription may be required.)